Acadia is a good sum-of-the-parts story with bad news mostly priced in and potential positive catalysts on the near-term horizon.
Eyenovia and BioDelivery Sciences are their targets.
Plus, the intersection of rising inflation and a slowing velocity of money give us reason for pause.
For now I would take a wait and see approach.
It may have a tough pill to swallow right now, but I'm still optimistic about psilocybin in general, and especially Cybin.
Let's review areas that are hot, those that are not, and how to position though January.
Let's look at the rookie mistake the biopharma made on Monday, and what makes the company still hold promise for investors -- if it explains its C-suite moves.
Let's see how far this pharma name could fall, even as it plays a leading role in the battle against the pandemic.
I'm going to offer a cautious trade on this name.
BioMarin has turned into a synthetic dividend play that has been returning yields in the low teens every six months or so.